luteinizing hormone levels as an indicator of the timing of antagonist administration in a gonadotropin-releasing hormone antagonist protocol

Background objective: gonadotropin-releasing hormone acts on the anterior pituitary and promotes the release of both follicle-stimulating hormone (fsh) and luteinizing hormone (lh), both of great importance in the ovarian cycle.materials methods: in a prospective cross-sectional study conducted at the high institute for infertility diagnosis and assisted reproductive technologies / al-nahrain university and kamal al-sameraie hospital for infertility and in vitro fertilization, baghdad, iraq during the period from april 2022 to april 2023, women received rfsh in a single daily dose of (150-300 iu) for ovarian stimulation. women in groups b and c received ovarian stimulation antagonists, while those in group a did not.results: both clinical and ongoing pregnancy rates were measured for each group. a positive hcg test was found in 27 (79.4%) in group a while it was positive in 19 (55.9%) in group b with a significant difference (p=0.03), clinical pregnancy was 25 (73.5%) in group a while it was positive in 17 (50.0%) in group b with a significant difference (p=0.04), and ongoing pregnancy was found in 24 (70.6%) in group a while it was positive in 15 (44.1%) in group b with significant difference (p=0.01).conclusion: women with lh <4 iu presented with a significantly higher pregnancy rate than those with ≥4 iu, and do not need gnrh antagonist addition as co-treatment.